09Nov

Member Press Release- Biofortuna double their manufacturing capacity

BIOFORTUNA DOUBLE THEIR MANUFACTURING CAPACITY

 

1st November 2021

 

Biofortuna (Deeside UK), a specialist contract development and manufacturing partner to the IVD and point of care testing sectors, has more than doubled its manufacturing capacity following its relocation to new state-of-the-art facilities in Deeside, North Wales.

The purpose-built facilities have been designed by the Company to provide the most efficient and modern manufacturing laboratories from which to meet the evolving needs of the world’s leading IVD and point of care businesses.

The new premises provide 450m³ of class-leading, humidity controlled clean room environment for formulation, dispensing, manufacturing and analysis of more than 10 million reactions per week.

Dr Nick Ash, Biofortuna Chief Executive Officer commented “This multi-million-pound investment demonstrates our ambition and commitment to become the sectors’ leading support specialist, helping our customers to accelerate their diagnostic development programmes from concept to commercialisation”.

Paul Williams, Head of Sales added “This facility will position Biofortuna as one of the leading outsourced providers of genomic services, custom assay development and contract manufacturing. It has been designed to expand our turn-key capabilities and provide our customers with a scalable resource to develop and manufacture their assays, particularly in the point of care and de-centralised IVD testing space”.

 

About Biofortuna

Biofortuna is a specialist contract development and manufacturing organisation providing genomic services, custom development and manufacturing support to the IVD, consumer health, life sciences and pharma biotech sectors. The Company is ISO 17025 and ISO 13485 accredited

Related

New Blood Collection Tubes Stabilise Nucleated Blood Cells

The new Streck Cell-Free DNA BCT® CE blood collection tubes, now available in the UK from Alpha Labo...

Read More >

A recent review by MIP Diagnostics Founder Sergey A. Piletsky from the University of Leicester and colleagues from Animal Health Research Institute

A recent review by MIP Diagnostics Founder Sergey A. Piletsky from the University of Leicester and c...

Read More >

EKF expands geographical reach of PCT test for early sepsis detection

Cardiff, UK – 2nd May 2017 – EKF Diagnostics, the global in vitro diagnostics company, announces t...

Read More >

Mologic receives a $4.8m grant to establish the centre for advanced rapid diagnostics ("card")

Mologic is pleased to announce that we are in receipt of a grant from the Bill & Melinda Gates Found...

Read More >